Researchers sought to determine whether thermography can reliably and effectively distinguish between allergic and irritant contact dermatitis.

The primary outcome of the study included identifying somatic mutations linked with cherry angiomas.

Further research is needed to analyze the mechanisms that are needed for an effective intervention program.

HLA-C*06:02 status is a predictive biomarker that influences response to adalimumab and ustekinumab in patients with psoriasis.

Obesity is an independent risk factor for the development of psoriasis and is associated with a worse prognosis.

In the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, and 12.

Of the 3 interventions, only patients who received the polyherbal combination tablets showed a significant decrease in facial redness of 40% compared with baseline

Desoximetasone with and without phone reminders was associated with clinical improvement in both psoriasis and atopic dermatitis.

The median total charges submitted to Medicare increased, but there was not a significant increase in the actual amount paid from Medicare.

The 15 risk loci linked to acne vulgaris in this study account for approximately 3% of phenotypic variance.